PMGC (ELAB) Holdings' subsidiary Northstrive Biosciences has initiated a groundbreaking preclinical investigation to evaluate the therapeutic potential of their novel engineered probiotic, EL-32, in combination with the popular weight loss drug semaglutide. The company has secured a research agreement with a contract research organization (CRO) specializing in metabolic disorders to conduct the study.
The research aims to address a significant challenge in current obesity treatments by exploring EL-32's potential to maintain muscle mass while promoting fat loss when used alongside GLP-1 receptor agonists like semaglutide. This combination approach could represent a significant advancement in obesity treatment strategies.
Study Design and Objectives
The investigation, formally titled "Effects of the test agent EL-32 administered either alone or in combination with semaglutide, on glycemic control and body composition in DIO mice," will utilize C57BL6/J mice as the experimental model. The study design incorporates multiple treatment arms to evaluate the effects of EL-32 both as a monotherapy and in combination with semaglutide.
Key endpoints of the study include:
- Changes in body composition
- Glycemic control parameters
- Comparative analysis between monotherapy and combination treatment
- Assessment of metabolic progress across different treatment groups
Research Timeline and Deliverables
Under the terms of the research agreement, the CRO will conduct the preclinical study and provide comprehensive results to Northstrive Biosciences within three months of study completion. The agreement includes the delivery of a detailed report documenting all research findings and methodologies employed during the investigation.
Therapeutic Potential and Market Implications
The development of EL-32 represents a novel approach to obesity treatment, particularly when combined with established GLP-1 receptor agonists. This strategic combination could potentially address one of the main concerns associated with current weight loss therapeutics – the preservation of lean muscle mass during weight reduction.
The collaboration between Northstrive Biosciences and the specialized CRO demonstrates the company's commitment to advancing innovative solutions in the metabolic disease space. Success in this preclinical phase could pave the way for further development and potential clinical trials of this unique therapeutic approach.
